Intravenous Thrombolysis With Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Acute Non-large Vessel Occlusion in Extended Time Window--A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial
This study is designed to evaluate the efficacy of IV rhTNK-tPA between 4.5 to 24 hours from symptom onset in patients presenting with a non-large vessel occlusion ischemic stroke.
• Clinical diagnosis of acute ischemic stroke
• Age≥18 years
• Pre-stroke mRS score≤1 points
• Disabling stroke defined as follows:
‣ Baseline NIHSS score 6-25 at the time of randomization,
⁃ Or NIHSS 4-5 with disabling deficit (e.g. hemianopia, aphasia, loss of hand function) as determined by the managing clinician
• Onset (last-seen-well) time to treatment time between 4.5 and 24 hours
• Written informed consent from patients or legally responsible representatives
• The presence of a Target Mismatch on CT perfusion: ischemic core volume\<50ml (defined as rCBF\<30%), mismatch ratio≥1.2 (Tmax\>6 sec lesion/core volume lesion), mismatch volume≥10ml